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Weak with Sex: Sexual Intercourse as a Trigger for Cataplexy
Abstract
Introduction. Sudden, often positive emotions are typical triggers for cataplexy in patients with
narcolepsy-cataplexy (NC). Cataplexy during sexual intercourse and orgasm (orgasmolepsy) has been
previously reported, but its frequency and characteristics are poorly known. Aim. To assess frequency
and features of loss of muscle tone during sexual intercourse in a series of patients with NC, other
sleep-wake disorders, and healthy controls. Methods. Review of sleep questionnaires (including the
Stanford Cataplexy Questionnaire) of 75 subjects (29 with NC, 26 with other sleep-wake disorders, and
20 healthy controls), followed by an interview with specific focus on muscle loss during sexual activity
in suspicious cases. Main Outcome Measures. Cataplexy during sexual intercourse and orgasm
(orgasmolepsy). Results. Orgasmolepsy was reported by three NC patients (two female, one male), one
male patient with behaviorally induced insufficient sleep syndrome (BIISS) and cataplexy-like
symptoms, and none of the healthy controls. In the two female NC patients, orgasmolepsy occurred by
each sexual intercourse, and the male patient reported orgasmolepsy only when in a relationship
involving emotional commitment and trust. In the patient with BIISS and orgasmolepsy, cataplexy-like
symptoms involved unilaterally upper or lower limbs in association with negative emotions or sports
activities. Conclusions. Cataplexy during sexual intercourse is a distinct feature of NC, which can,
however, be reported rarely also by patients with other sleep-wake disorders. Insufficient arousal may
favor the occurrence of cataplexy and cataplexy-like symptoms, including orgasmolepsy. Hypocretin
deficiency and reward dysregulation in narcolepsy may further facilitate this phenomenon and
contribute to its repetitive occurrence. Poryazova R, Khatami R, Werth E, and Bassetti CL. Weak with
sex: Sexual intercourse as a trigger for cataplexy. J Sex Med **;**:**-**.
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Abstract:   
Introduction: Sudden, often positive emotions are typical triggers for cataplexy in patients 
with narcolepsy-cataplexy (NC). Cataplexy during sexual intercourse and orgasm 
(orgasmolepsy) has been previously reported, but its frequency and characteristics are poorly 
known.  
Aim: To assess frequency and features of loss of muscle tone during sexual intercourse in a 
series of patients with NC, other sleep-wake disorders and healthy controls. 
Methods: Review of sleep questionnaires (including the Stanford cataplexy questionnaire) of 
75 subjects (29 with NC, 26 with other sleep-wake disorders, and 20 healthy controls) 
followed by an interview with specific focus on muscle loss during sexual activity in 
suspicious cases.  
Main outcome measures: Cataplexy during sexual intercourse and orgasm (orgasmolepsy). 
Results: Orgasmolepsy was reported by three NC patients (two female, one male), one male 
patient with behaviorally induced insufficient sleep syndrome (BIISS) and cataplexy-like 
symptoms and none of the healthy controls. In the two female NC-patients orgasmolepsy 
occurred by each sexual intercourse and the male patient reported orgasmolepsy only when in 
a relationship involving emotional commitment and trust. In the patient with BIISS and 
orgasmolepsy, cataplexy-like symptoms involved unilaterally upper or lower limbs in 
association with negative emotions or sports activities  
Conclusion: Cataplexy during sexual intercourse is a distinct feature of NC which can 
however be reported rarely also by patients with other sleep-wake disorders. Insufficient 
arousal may favor the occurrence of cataplexy and cataplexy-like symptoms, including 
orgasmolepsy. Hypocretin deficiency and reward dysregulation in narcolepsy may further 
facilitate this phenomenon and contribute to its repetitive occurrence. 
 
 
Introduction:  
Narcolepsy-cataplexy (NC) is a disabling life-long sleep-wake disorder, characterized by 
excessive daytime sleepiness (EDS) and sudden loss of muscle tone triggered by emotions 
(cataplexy) [1]. Accessory symptoms include sleep paralysis, hypnagogic hallucinations and 
fragmented nighttime sleep. Cataplexy is specific for narcolepsy and its presence allows 
diagnosing NC on clinical grounds. Sleep studies in NC, in particular the occurrence of two or 
more sleep onset REM periods (SOREMPs) in the multiple sleep latency test (MSLT) is 
characteristic though not specific for NC [2]. Two biological markers are tightly associated 
with cataplexy: there is a strong association to the human leukocyte antigen system (HLA) 
and a loss of the hypothalamic neuropeptide hypocretin (also called orexin) in the 
cerebrospinal fluid (CSF). The genetic marker HLA DQB1*0602 is found in 98% of 
narcolepsy patients with cataplexy compared to 35% of healthy controls [3]. CSF hypocretin 
levels <110pg/ml are considered low or undetectable and are diagnostic for narcolepsy, 
between 110 - 200pg/ml intermediate and levels >200 pg/ml are considered normal [4].  
Treatment is symptomatic and includes stimulant drugs (amphetamine analogs and modafinil) 
targeting EDS and antidepressants or sodium oxybate to treat cataplexy. Amphetamine 
analogs enhance adrenergic and dopaminergic transmission by blocking reuptake and 
stimulating release at the presynaptic terminals [5,6]. Modafinil’s mechanism of action is 
complex and distinct from other wakefulness-promoting drugs. It modulates glutamate, 
GABA, histamine and hypocretin, and to the lesser extent the monoaminergic systems [7]. It 
has been shown, that dopaminergic D1 and D2 receptors are essential for the arousal effect of 
modafinil [8]. The anticataplectic effect of antidepressants is associated mainly with 
adrenergic uptake inhibition, while serotonergic uptake blockers are less effective [9]. Sodium 
oxybate may act on GABAB receptors or its own receptors and may also modulate 
dopaminergic neurotransmission [10].  
Hypocretin is involved in various basic functions such as sleep-wake regulation, feeding, 
reward and drug-seeking behavior. Dopaminergic system is essential for motor control but it 
also promotes wakefulness and plays an essential role in reward processing and in male 
sexual response [11,12]. The use of dopamine agonists can lead to hypersexuality [13]. The 
two systems are tightly interconnected. Hypocretin efferents from the lateral hypothalamus 
innervate midbrain dopaminergic nuclei, and dopamine cell bodies express hypocretin 
receptors [14,15]. Activation of hypocretin-containing neurons in the ventral tegmental area 
(VTA) leads to the direct activation of mesolimbic dopamine neurons and is probably 
associated with the development of rewarding effects [16]. Dopamine itself modulates the 
firing of hypocretin neurons.  A dose-dependent dual feedback mechanism between the two 
systems is suggested where D1- and D2-like receptors have opposing effects on the excitatory 
presynaptic terminals impinging onto hypocretin/orexin neurons [17].  
In NC the loss of CSF hypocretin is tightly associated with cataplexy, and strong emotions. 
Positive emotions (such as laughing, joking and elation) are typical triggers of cataplexy 
suggesting a role of hypocretins in emotional motor control. Sexual excitement and orgasm 
are also associated with strong positive emotions. Complete loss of muscle tone during sexual 
intercourse was first described in a single case report of a male narcolepsy patient in 1928 by 
Rothfeld [18]. He named the phenomenon orgasmolepsy. A year later Levin reported a case 
with partial cataplexy in a male narcolepsy patient during sexual intercourse and masturbation 
[19]. Since then loss of muscle tone during sexual intercourse has been rarely reported in the 
literature [20-22] but without any detailed description of its characteristics. It has also been 
suggested recently that hypocretins are involved in male sexual behavior in rats [23,24].  
Local application of hypocretin in the medial preoptic area increased sexual arousal and 
copulatory performance [23] while systemic hypocretin blockade resulted in impaired 
copulatory behavior. In addition, hypocretins dose-dependently increased neuron firing in the 
ventral tegmental area [24], an area which is known to be involved in sexual behavior. The 
human “sexual response cycle” consists of four sequential phases: sexual excitement, plateau, 
orgasm, and resolution. Each phase of the sexual cycle has its own neural substrate as 
assessed by PET [25-28] and fMRI [29,30] studies. Distinct activation patterns have been 
observed during onset and maintenance of sexual arousal in various brain regions including 
the amygdala, hippocampus, hypothalamus, insular and cingulate cortex, putamen, the cortical 
regions. These regions are known to be targeted also by the hypocretins.   
Cataplexy-like symptoms have also been reported by non narcoleptic subjects, more often in 
hypersomnolent patients then in healthy controls [31]. Similarly, orgasmolepsy has also been 
reported in patients with various sleep disorders (mainly sleep apnea) [21] but not in healthy 
controls. 
The aim of the present study was to assess the frequency of and to obtain detailed clinical 
information on loss of muscle tone during sexual intercourse (orgasmolepsy) in a series of 
NC-patients, in patients with EDS/fatigue due to various sleep disorders and in healthy 
controls.  
Patients and methods:  
Different questionnaires (including the Sleep Questionnaire and the Stanford Cataplexy 
Questionnaire [21]) completed by 77 adults (29 with NC (11 male), 28 with different sleep 
disorders and excessive daytime sleepiness (EDS) or/and fatigue (19 male) and 20 healthy 
controls (9 male) were reviewed. The sleep questionnaire includes 69 questions addressing 
sleep-wake habits and complaints. The answers provide information on symptoms/signs 
suggestive of sleep apnea (SA), EDS, narcolepsy, different parasomnias, insomnia and 
disturbances of the sleep-wake rhythm. Possible answers include “yes” and “no” or provide a 
rating on a 5 point scale depending on the frequency of occurrence (“almost always”, “often”, 
“occasionally”, “seldom” or “never”. Four validated scores are included in the questionnaire. 
The Epworth Sleepiness Scale (ESS), a scale for assessment of subjective EDS based on eight 
questions on the urge to sleep in various life situations [32]. Each question is rated on a 4 
point scale ranging from 0 to 3 points, thus resulting in a maximum sum score of 24 points. A 
cut-off score of 10 is considered abnormal. The Sleep Apnea Scale of the Sleep Disorders 
Questionnaire (SA-SDQ) is a screening instrument for obstructive sleep apnea. The SA-SDQ 
consists of 12-items for sleep-related breathing disorders and includes the well-known risk 
factors of age and body mass index (BMI). Cut-off scores of 32 for women and 36 for men 
(range is 12–60) provided a sensitivity of 85% and a specificity of 72% for males and 88% 
and 81% for females, respectively [33]. The 11-item Ullanlinna Narcolepsy Scale (UNS) is a 
widely used screening instrument for narcolepsy [34]. A cut-off of 14 has been shown to have 
a high sensitivity (100–96%) but a variable specificity (99–56%) for patients with narcolepsy-
cataplexy [31,33]. The Swiss narcolepsy score (SNS) is based on five questions, a score <0 
had a sensitivity and specificity for narcolepsy of 96 and 98% respectively [31]. The Stanford 
cataplexy questionnaire contains 51 items on cataplexy, including questions pertaining to 
cataplexy triggers, localization, duration and frequency of the attacks [21].  The subjects who 
reported on orgasmolepsy were contacted to obtain more details about their complaints. 
The available clinical data included neurological examination, overnight video-
polysomnography (PSG) and multiple sleep latency test (MSLT), treatment was also 
documented. Hypocretin CSF levels were available in 28 patients (of them 21 with NC) and 
HLA DQB1* 0602 in 47 patients (29 of whom had NC). The diagnoses of the patients with 
sleep disorders included: behaviorally induced insufficient sleep syndrome (BIISS) n=13, 
EDS of unknown origin n=3, narcolepsy-like features n=3, monosymptomatic narcolepsy (i.e. 
without cataplexy) n=2, depression and hypersomnia n=2, other n=5.  
All narcolpepsy patients and all control subjects were a part of a large study on narcolepsy 
including cataplexy and its characteristics. The study was approved by the local ethics 
committee and written informed concent was obtained from all subjects. The patients with 
sleep disorders other then narcolepsy were retrospectively analyzed from the pool of our sleep 
laboratory. Before filling in our questionnaires they signed an informed concent, that the data 
obtained during their clinical examinations can be used for research purposes at a later stage. 
 
Main outcome measures:  
Cataplexy and cataplexy-like episodes during sexual intercourse (orgasmolepsy). 
 
Results:  
Loss of muscle tone during sexual intercourse was reported by three NC patients (two female, 
one male), and by one patient with BIISS, but by none of the healthy controls. Four NC 
patients and three patients with sleep disorders were uncertain about the occurrence of muscle 
weakness during sexual intercourse. 
All 29 NC patients were HLA DQB1* 0602 positive, 20/21 had low or undetectable 
hypocretin CSF levels. HLA DQB1* 0602 was positive in 9/18 patients with sleep disorders 
other than NC, 1/7 patients had intermediate hypocretin level in CSF (a patient with 
depression and hypersomnia). Demographic and clinical data are presented in Table 1. 
We were able to contact the three NC patients, reporting orgasmolepsy and obtain a detailed 
description of their complaints. 
Patient 1: This 23-year-old woman developed EDS at the age of 16, first episodes of partial 
cataplexy with sagging of the jaw, head drooping, knees and elbows weakness during laughter 
occurred at the age of 19. The patient presented at the outpatient clinic with EDS (Epworth 
sleepiness score, ESS 17), partial cataplexy with a frequency of 3-4/week, usually lasting a 
few seconds, sleep paralysis 1/month and as a leading and most embarrassing symptom, 
orgasmolepsy. Loss of muscle tone occurred during each sexual intercourse, was always 
complete and lasted longer than the partial cataplexy, but not longer than 30 seconds. The 
patient never fell asleep and remained conscious. She was positive for HLA DQB1*0602 and 
her CSF hypocretin was undetectable. Videopolysomnography (PSG) showed a sleep onset 
REM (SOREM) episode, multiple sleep latency test (MLST) documented 3 of 4 SOREM 
episodes. The patient was treated with sodium oxybate, which improved cataplexy in general, 
but she was not able to verify its efficiency on orgasmolepsy. 
Patient 2: This 24-year-old woman developed EDS, sleep paralyses and hypnagogic 
hallucinations at the age of 18. First episodes of cataplexy with sagging of the jaw, head 
drooping, buckling of the knees and falls, mainly triggered by laughter occurred at the age of 
21. The patient presented at the outpatient clinic with EDS (ESS 19), partial and complete 
cataplexy with a frequency of 3-4/day, usually lasting a few seconds, everyday sleep paralysis 
and hypnagogic hallucinations 2-3/week. Orgasmolepsy occurred during each sexual 
intercourse, was always complete and lasted longer than her partial cataplexies, but not longer 
than 30 seconds. The patient never fell asleep but sometimes she thought she was dreaming. 
She was HLA DQB1*0602 positive, her CSF hypocretin was 107pg/ml. PSG showed a 
SOREM episode, MSLT documented 3 of 5 SOREM episodes. The patient was first treated 
with Modafinil 150mg/day with satisfactory effect on EDS but no change in other narcolepsy 
symptoms. After treatment with sodium oxybate 4.5g/day was initiated no more cataplexy 
occurred, including orgasmolepsy. Sleep paralyses or hallucinations were no longer present.  
Patient 3:  This 25-year-old man developed EDS at the age of 18 together with partial 
cataplexy with head drooping, knee and elbow weakness triggered by laughter, anger and 
surprise. He presented with severe EDS (ESS 18) and partial cataplexy with a frequency of 
about 1/week, usually lasting a few seconds. To prevent cataplexy he tried to suppress 
laughter. The patient described cataplexy during sexual intercourse, which occurred only with 
partners he trusted and was emotionally committed to. He did not experience such symptoms 
with new partners. Loss of muscle tone in these occasions was complete, he did not fall asleep 
and was able to perceive his surroundings. He was HLA DQB1*0602 positive, CSF 
hypocretin was not assessed. PSG did not show a SOREM, MSLT documented 4 out of 4 
SOREM episodes. The patient was treated previously with Modafinil 200mg/day with no 
effect on EDS and refused further treatment. 
Patient 4: This 43-year-old man presented with low back pain, paraesthesia in both calves and 
hands and nocturnal leg cramps. In addition he reported EDS (ESS 15) and possible breathing 
problems at night. PSG showed normal sleep latency (19 min), high sleep efficiency (96%), 
normal apnea/hypopnea index (AHI) =8/h and periodic limb movements in sleep index = 4/h. 
MSLT documented two SOREM episodes and shortened mean sleep latency of 1.6 minutes. 
He was negative for HLA DQB1* 0602 and had normal CSF hypocretin level (417pg/ml). 
Actigraphy showed poor sleep hygiene (as defined by late, irregular and highly variable (>3h) 
bed and wake-up times) and BIISS, which was retained as most likely diagnosis. On Stanford 
cataplexy questionnaire he reported cataplexy-like symptoms with a frequency of 3-4/week 
including muscle weakness in one or both legs or arms, dropping things from his hands and 
blurred speech when being angry, worried, frightened, during and after sports activities and in 
romantic situations as well as during sexual intercourse. During these episodes he was not 
sure whether he could hear and whether he was awake or asleep. He did not appear for his 
planned visits at the outpatient clinic and could not be contacted for further details 
 
Discussion: 
Orgasmolepsy is a disturbing and highly embarrassing symptom reported by 10% (3/29) of 
our series of NC patients. This frequency is slightly lower compared to the scarce data in the 
literature, 22- 31% in two earlier studies from Stanford (40/130 and 13/58 respectively) 
[20,21] and similar to that found in a German study, 11% (5/47) [22]. A detailed description 
of orgasmolepsy and its relationship to other cataplexy features could be obtained in three NC 
patients. They all had frequent partial cataplexy (1/week to 3-4/day) but only one patient 
reported frequent generalized cataplexy with falls. Cataplexy triggers were mainly strong 
positive emotions, laughter being the most common. EDS was severe in all of them (resp. 
ESS 17, 18 and 19). The two female patients also experienced sleep paralysis and 
hallucinations. In one patient sodium oxybate proved efficient for all REM-sleep 
dysregulation symptoms with remarkable effect on cataplexy and orgasmolepsy, but only 
mild effect on sleepiness.  
Orgasmolepsy was reported also by a patient with BIISS with EDS and cataplexy-like 
symptoms. Although we could not follow up this patient for further details, these findings 
confirm that both cataplexy-like symptoms and orgasmolepsy may occur also in non-
narcoleptic subjects with other sleep disorders (mainly sleep apnea [21]) and , rarely, even 
normal controls. A higher frequency of these episodes in hypersomnolent patients [31] 
suggests that EDS and insufficient arousal may serve as a gating mechanism for the 
occurrence of cataplexy-like symptoms including orgasmolepsy [35]. Thus a sexual medicine 
specialist may encounter orgasmolepsy as a manifestation of cataplexy not only in NC 
patients but also in patients with EDS of different origin. In NC patients anticataplectic drugs 
(antidepressants or sodium oxybate) should be effective also for orgasmolepsy. In sleepy 
patients EDS should be addressed depending on its cause. For example in sleep apnea patients 
continuous positive airway pressure (CPAP) treatment should be initiated, in patients with 
BIISS behavioral measures with optimizing the sleep hygiene (regular bed and wake-up 
times, sufficient duration of the nighttime sleep) should be discussed.  
In the male NC patient orgasmolepsy only occurred with a partner in a relationship with 
emotional commitment and trust. Similar, both female patients experienced orgasmolepsy 
with their partners living in a stable partnership. Differential neural activation of various brain 
regions in men and women has been observed in response to visual sexual stimuli [22] but not 
during orgasm [36]. Therefore, the sexually differentiated neural activity during sexual 
arousal that precedes orgasm is more likely to reflect the cognitive processing of sexual 
stimuli, such as motivation and desire, rather than physiological arousal [37]. Both sexes 
experienced orgasmolepsy with their partners living in a stable partnership suggesting that 
emotional disinhibiton and diminished self control requires a state of intimacy as a 
prerequisite for orgasmolepsy. Deactivation in the prefrontal cortex, an area responsible for 
self-control, has been reported during sexual arousal and orgasm, suggesting the presence of 
emotional disinhibiton [26,27]. Amygdala deactivation has been observed during various 
euphoric states, including orgasm and sexual arousal [25], cocaine rush [38] and when 
volunteers reportedly deeply in love viewed pictures of their loved ones [39]. Hence 
amygdala deactivation has been proposed to be responsible for euphoric states. On the other 
hand, structural and functional amygdala abnormalities in NC have been reported in both 
animals [40] and humans [41]. A recent fMRI study found an exaggerated amygdala response 
to humor and dysfunctional amygdala-hypothalamic interaction in hypocretin deficient 
narcolepsy patients with cataplexy [42]. In narcoleptic dogs cataplexy-related neuron 
populations in the amygdala are thought to mediate cataplexy via interactions with meso-
pontine regions controlling atonia [40]. We therefore hypothesize that orgasmolepsy may be 
related to persisting amygdala firing during sexual intercourse and consequent disinhibition of 
pontine and medullar atonia-generating neurons. Considering the existence of dense 
hypocretinergic projections to the medial preoptic area, the bed nucleus of stria terminalis and 
the ventral tegmental area [14], known to be part of reward networks including the ones 
involved in sexual arousal and orgasm, a role for hypocretin in orgasmolepsy can be 
suggested. Hypocretin deficiency and impaired reward processing in patients with NC may 
facilitate the occurrence of orgasmolepsy.  
 
Conclusion: 
Cataplexy during sexual intercourse is a distinct feature in NC patients. Less commonly 
orgasmolepsy- is reported also by patients with excessive daytime sleepiness of other origin. 
Thus a sexual medicine specialist may encounter orgasmolepsy not only as a manifestation of 
cataplexy in NC patients but also in patients with EDS of different origin. Treatment options 
in narcolepsy include anticataplectic drugs and in EDS depend on its cause. 
Insufficient arousal may serve as gating mechanism for cataplexy and cataplexy-like 
symptoms, including orgasmolepsy. Hypocretin deficiency and reward dysregulation in 
narcolepsy may facilitate the phenomenon and contribute to its repetitive occurrence. 
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Table 1: Demographic and clinical characteristics of patients with narcolepsy with cataplexy 
(NC), other patients with sleep-wake disorders (SD) and controls (C). 
  NC, n=29 SD, n=28 C, n=20 
Age, years 38.7 ± 16.3 37.1 ± 12.3 31.9 ± 8.2 
Body mass index 27.7 ± 6.3 25.5 ± 5.3 27.8 ± 7.2 
Epworth Sleepiness Score [32] 16.1 ± 3.6 14.8 ± 5.1 6.7 ± 2.7 
Ullanlinna Narcolepsy Score [34] 23.8 ± 7.5 13.4 ± 5.4 5.8 ± 2.7 
Swiss Narcolepsy Score [31] -33.4 ± 33.9 8.4 ± 25.9 24.5 ± 11.7 
SAS-SDQ [33] 30 ± 7.9 30.7 ± 8 25.9 ± 8.5 
Cataplexy frequency 4.5 ± 1.1 2.3 ± 2.2 0.4 ± 0.9 
Sleep latency, min 6.3 ± 6.8 19.2 ± 17.8 NA 
REM latency, min 33 ± 74.7 95.9 ± 63.7 NA 
nocturnal SOREM 21/29 2 /28 NA 
mean sleep latency in MSLT, min 2 ± 1.3 6.6 ± 4.3 NA 
Number of SOREM in MSLT 3.2 ± 1 0.8 ± 1.4 NA 
 
 
MSLT – multiple sleep latency test, SOREM – sleep onset REM, , SAS-SDQ – sleep apnea 
syndrome sleep disorders questionnaire , NA – not available. Cataplexy frequency is scaled as 
follows: 1 – less than 1/year, 2 – 1/year, 3 – 1/month, 4 – 1/week, 5 – 3-4/week, 6 – more than 
1/day 
 
 
